Table 4.
Summary of Relapse-free Survival
| Dose Group
|
|||
|---|---|---|---|
| RFS Definition/Analysis Population | 3×105 | 1×106 | 3×106 |
| RFS from Date of CR11 | |||
| FAS | |||
| N | 3 | 3 | 6 |
| Median (range) | 105 (92, 525) | 156 (117, 800+) | 337 (176, 677+) |
| PP | |||
| N | 3 | 5 | |
| Median (range) | 309 (92, 525) | 156 (117, 800+) | 344 (183, 677+) |
|
| |||
| RFS from Date of CNDO NK Cell Treatment2 | |||
| FAS | |||
| N | 3 | 3 | 6 |
| Median (range) | 56 (27, 454) | 123 (29, 745+) | 240 (57, 560+) |
| PP | |||
| N | 2 | 3 | 5 |
| Median (range) | 241 (27, 454) | 123 (29, 745+) | 316 (94, 560+) |
NE=Not estimable.
1
RFS duration, defined as the interval from the date of study product infusion CR1 to the date of relapse (according to IWG criteria for AML) or death.
2
RFS duration also was analyzed using an updated definition of the interval from the date of study product infusion to the date of relapse (according to IWG criteria for AML) or death.